United States

Saving producers what matters most

Some producers focus on saving pigs. Others on practices that save time. And to others, it's all about money and the bottom line. While what matters most may vary by producer, choosing a respiratory disease treatment that helps save pigs, time and money is an important component of an anti-infective program.

"Selecting the right anti-infective program for your herd's situation is important," says Michael Senn, DVM, manager, technical services at Pfizer Animal Health. "It's critical to get an accurate diagnosis, and support the effective and judicious use of antibiotics in the livestock industry. At Pfizer Animal Health, we work hard to provide diagnostic support for our customers through funding and veterinary involvement."

Save Pigs. Save Time. Save Money.

As part of Pfizer Animal Health's comprehensive anti-infective portfolio, DRAXXIN® (tulathromycin) Injectable Solution helps producers save pigs, time and money.

"With just one dose, DRAXXIN fights five of the most common bacterial respiratory pathogens," Senn says. "It provides at least nine full days1 of activity to ensure growing pigs have every chance to be on the road to recovery."

One convenient treatment minimizes labor and handling stress while treating the five major bacterial causes of swine respiratory disease (SRD):

  • Actinobacillus pleuropneumoniae
  • Pasteurella multocida
  • Bordetella bronchiseptica
  • Haemophilus parasuis
  • Mycoplasma hyopneumoniae

DRAXXIN controls SRD in groups of pigs where SRD has been diagnosed and is associated with:

  • Actinobacillus pleuropneumoniae
  • Pasteurella multocida
  • Mycoplasma hyopneumoniae

In addition to fighting SRD, DRAXXIN has been shown to reduce mortality2 -- which can lead to more high-value pigs2 going to market.

To learn more about DRAXXIN saving pigs, time and money, visit PfizerPork.com/DRAXXIN.

The pre-slaughter withdrawal time for DRAXXIN in swine is five days. DRAXXIN should not be used in animals known to be hypersensitive to the product.

1. Benchaoui, HA, Nowakowski M, Sherington J, Rowan TF, Sunderland SJ. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharm Therapeutics 2004; 27:203-210.
2. Data on file, Study Report No. 1123R-60-07-283, Pfizer Inc.

Pfizer Animal Health, a business of Pfizer Inc., is a world leader in discovering and developing innovative animal vaccines, medicines, diagnostic products and genetic tests, investing an estimated $300 million annually in animal health product research and development. For more information about how Pfizer Animal Health works to ensure a safe, sustainable global food supply from healthy swine and other livestock, visit PfizerAH.com.